Approach Precision is power.
Our codon deoptimized live vaccine candidates overcome these drawbacks,
delivering all the benefits of live vaccines on short timelines and with unparalleled genetic stability.
Known benefits of live-attenuated vaccines
Live vaccines meet software-enabled codon deoptimization.
Codagenix is pushing this proven approach into the clinic and beyond by merging live-attenuated viruses with a novel codon deoptimization approach that leverages cutting-edge developments in synthetic biology and machine learning.
Our “death by a thousand cuts” approach takes the genetic sequence of the wild-type target and uses an AI-aided algorithm to compute the hundreds or thousands of sites where codons can be modified to produce the same amino acid sequence with lower translational efficiency. This process yields a small, testable number of candidate viral genomes that produce all the same proteins as the wild type but with far less virulence, exponentially accelerating timelines for candidate development.
Unlike traditional live vaccines, which contain only a small number of mutations, our codon deoptimized vaccines contain hundreds of intentionally placed edits, making it probabilistically impossible for the virus to revert to the wild-type phenotype.
Stable in vitro manufacturing, safe in vivo immunity.
Codagenix leverages decades-proven manufacturing for our vaccine and therapeutics. Our live-attenuated viruses can be effectively produced in cell culture which does not possess adaptive immunity at commercial scale in existing manufacturing facilities, stored in conventional cold chains and easily delivered to far reaches of the globe. They also have dose-sparing potential to accelerate the distribution of life-saving vaccines even further.
Codon pair modification allows us to ensure our virotherapeutics retain the exceptional safety profiles of oncolytic viruses observed across virus species. Recoded viral genomes provide a potent layer of tumor cell specificity, since viral replication is simultaneously sustained in tumor cells with defective innate immune sensing mechanisms and restricted in healthy cells.
In addition, the species-agnostic nature of the synthetic engineering platform allows us to choose the optimal virus for a tumor type based on receptor expression. This means that rather than a single oncolytic virus searching for a clinical indication, the Codagenix discovery platform is designed to identify novel virotherapeutics customized to a specific cancer type.
Virotherapeutics fit for purpose.
Codagenix’s virotherapeutics harness the natural ability of selected viruses to induce potent innate and adaptive immune responses. This modulates the tumor microenvironment in multiple ways, favoring anti-tumor immune responses.